Needham analyst Joseph Stringer raised the firm’s price target on Apellis Pharmaceuticals to $63 from $60 and keeps a Buy rating on the shares post the Q3 report. The firm says despite potential safety and competitive overhangs, it is encouraged that the vasculitis rates appear to have stabilized and remain very low, and Syfovre’s demand trajectory has re-accelerated in Q3. The analyst remains bullish on the Syfovre launch going forward and increased estimates following the quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis reports Q3 EPS ($1.17), consensus (85c)
- Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
- Apellis Pharmaceuticals call volume above normal and directionally bullish
- Biotech Alert: Searches spiking for these stocks today
- Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results